Played a lead role in the New Jersey Supreme Court In Re Accutane decisions, which were highlighted by Law360 in its “Top Cases of 2018." As counsel to amici curiae the Health Care Institute of New Jersey, New Jersey Business and Industry Association, Commerce and Industry Association of New Jersey, and New Jersey State Chamber of Commerce, successfully argued before the New Jersey Supreme Court that labels on the acne drug Accutane were adequate under New Jersey law; and that the state should adopt the Daubert factor-based approach for determining the admissibility of expert testimony. This landmark case changed New Jersey law on expert admissibility, and the Supreme Court’s decision relied upon and cited McCarter’s argument. Also briefed and successfully argued in McCarrell v. Hoffmann-La Roche that New Jersey’s two-year statute of limitations should apply in products cases involving a prescription medicine. In Re: Accutane Litigation, 235 N.J. 229 (2018); In Re: Accutane Litigation, 234 N.J. 340 (2018); McCarrell v. Hoffmann-La Roche, Inc., 227 N.J. 569 (2017)